All In Capital leads pre-seed round in healthcare infrastructure startup Tross
All In CapitalCompany
DeVCInvestor
All In Capital led a pre‑seed round in healthcare‑infrastructure SaaS startup Tross on August 20, 2026, with participation from DeVC; the amount raised was not disclosed.
All In Capital led a pre‑seed round in healthcare‑infrastructure SaaS startup Tross on August 20, 2026, with participation from DeVC. The undisclosed capital will fund accelerated product development, an expanded engineering team, and deeper integration with electronic health records (EHR) and payer portals.
Deal Terms
The round is classified as a pre‑seed venture funding round. While the exact raise size was not disclosed, the involvement of All In Capital—a firm known for early‑stage investments in AI‑enabled platforms—signals confidence in Tross’s API‑first approach to connecting AI applications with complex healthcare systems. DeVC’s participation adds a layer of strategic expertise in health‑tech scaling. The press release notes that the funds will be allocated to hiring additional engineers, building out new EHR and payer integrations, and expanding the company’s footprint in the U.S. market.
Market Context
Co‑founded by Padam Kataria and Meet Shah, Tross positions itself as the infrastructure layer for AI in healthcare, offering APIs that let AI vendors automate scheduling, referrals, claims processing, clinical documentation, and data extraction. The startup claims it is already working with multiple AI companies serving the U.S. market and is on track to enable more than 200,000 patient interactions this year across calls, referrals, scheduling, and back‑office workflows. This focus on workflow automation aligns with a broader surge in AI‑driven health‑tech solutions emerging from the Indian startup ecosystem, where peers such as Gurugram‑based Care.fi (Series A $8 M) and CARPL.ai ($10 M Series A) are scaling similar revenue‑cycle and AI‑deployment platforms.
Tross’s strategy of abstracting the complexity of EHR and payer integration into a reusable SaaS layer could lower time‑to‑market for AI health‑tech firms, a critical advantage in a market where regulatory compliance and data interoperability are major barriers. By expanding the number of supported health systems and the breadth of automatable workflows, Tross aims to become a de‑facto middleware for AI‑enabled care delivery, positioning itself for rapid adoption as hospitals and insurers accelerate digital transformation.
The pre‑seed round underscores continued investor appetite for early‑stage health‑tech infrastructure that can unlock scale for downstream AI applications. With the capital now in hand, Tross is poised to deepen its U.S. presence, broaden its integration catalog, and potentially attract follow‑on funding at higher valuations as it demonstrates measurable impact on patient‑interaction volumes and workflow efficiency.
Why It Matters
Tross’s infusion of pre‑seed capital puts it in direct competition with other AI‑focused health‑infrastructure players that are also racing to become the default integration layer for providers and payers. For Care.fi, which recently closed an $8 M Series A to scale its revenue‑cycle management platform, Tross represents a potential upstream supplier of the same API capabilities that Care.fi currently builds in‑house. If Tross can deliver a broader set of integrations faster, it may capture a share of the integration market that would otherwise be built by competitors, forcing them to either partner with Tross or develop parallel solutions.
For emerging entrants like MediKno, which secured a pre‑seed round in June, Tross’s progress raises the bar for product depth and partnership velocity. Investors will likely scrutinize Tross’s ability to lock in early adopters, as a strong customer base could translate into network effects that make its platform indispensable for AI vendors. In turn, this could accelerate consolidation in the health‑tech infrastructure space, with larger SaaS operators eyeing acquisition opportunities once Tross demonstrates scalable revenue and high net‑revenue retention from its integration services.
Key Points
- All In Capital led the pre‑seed round in Tross, with DeVC also participating
- The round size was undisclosed, but the capital will fund product development, engineering hires, and new EHR/payer integrations
- Tross aims to enable over 200,000 patient interactions this year through AI‑driven workflow automation
- The startup positions itself as an API‑first infrastructure layer for AI health‑tech companies in the U.S. market
- Tross joins a wave of Indian health‑tech startups raising capital for AI‑powered workflow automation, alongside Care.fi and CARPL.ai
Analysis
Tross’s pre‑seed raise, while undisclosed, highlights the premium investors place on infrastructure SaaS that removes friction for AI health‑tech applications. Early‑stage valuations for AI‑enabled health platforms typically range from $5 M to $15 M pre‑money, implying that the capital injected could represent a 10% to 20% equity stake. If Tross can translate its integration capabilities into recurring subscription revenue, it could quickly achieve gross margins above 80%—a hallmark of pure‑play SaaS businesses. The ability to automate 200,000+ patient interactions suggests a sizable addressable market; even a modest $0.10 per interaction fee would generate $20 K in monthly recurring revenue, scaling rapidly as more AI vendors plug into the platform. For investors, the deal offers a foothold in a niche where data interoperability, regulatory compliance, and AI adoption intersect—areas that are expected to see double‑digit growth through 2030. Operators in the space should watch Tross’s roadmap for expanding workflow coverage, as broader integration breadth can become a defensible moat that drives higher net‑revenue retention and upsell potential. The round also signals that capital is flowing to early‑stage health‑tech infrastructure, encouraging other founders to prioritize API‑centric models that can serve multiple downstream AI products, thereby unlocking higher valuation multiples as the market matures.